OpenEvidence has raised $735M across 4 funding rounds. The latest round valued OpenEvidence at $12B post-money, with Thrive Capital, DST Global on the lead line.
OpenEvidence has raised money from Sequoia, Kleiner Perkins, Google Ventures, Nvidia, Andreessen Horowitz, Thrive, and Mayo Clinic, among other investors. In July 2025 the company raised $210 million to expand its AI agents for medical research.
4 funding rounds, the latest highlighted.
OpenEvidence was founded in 2022, United States.
A primary round — the company sells new shares to investors it selects. $75M raised, led by Sequoia Capital.
Coatue, Conviction, and Thrive Capital participated. $210M raised, led by GV (Google Ventures), Kleiner Perkins.
A primary round — the company sells new shares to investors it selects. $200M raised, led by Google Ventures.
A primary round — the company sells new shares to investors it selects. $250M raised, led by Thrive Capital, DST Global.
No filing has been made.
4 dated rounds, newest first.
Thrive CapitalLEAD
DST GlobalLEAD
Google VenturesLEAD
GVLEAD
Kleiner PerkinsLEADSSequoia CapitalLEAD
Nvidia
Blackstone
Craft Ventures
Mayo Clinic
Coatue
ConvictionThe routes section explains what is realistically available for a company at this stage.
No. OpenEvidence is a private company; its shares do not trade on a public exchange.
The last valuation is $12B.
Lead investors for each round are in the funding timeline.
Perpetual markets for stocks, gold, indices and pre-IPO names — settled on-chain, no wallet-to-exchange transfers.
